The Peeper laboratory is in the brand-new Division
of Molecular Oncology and Immunology at NKI. We use function-based,
genome-wide experimental strategies to develop rational
combinatorial cancer treatment, targeting both cancer and immune
cells. By screening for novel therapeutic targets and predictive
biomarkers, we aim to achieve more durable clinical responses for
patients. On the one hand, we're increasing our understanding of
how cancer cells rewire their signaling networks, to expose and
exploit new pharmacologically tractable tumor susceptibilities,
also in the context of immunotherapy. On the other, we're
manipulating various cell types from the patient's own immune
system to boost their specific cytotoxicity towards tumor cells.
With these approaches, we are developing new rational combinatorial
therapies, which simultaneously eliminate the patients' tumor and
harness their immune system.
PI Daniel Peeper and Christian Blank (a
clinician researcher) recently engaged in a partnership to
complement our basic, translational and clinical fields of
expertise. This warrants not only the clinical relevance of our
research questions, but also facilitates translation of our
laboratory findings (therapeutic targets, prognostic and predictive
biomarkers) to the clinic, particularly by initiating trials that
are run here at NKI.
More about the Daniel Peeper group